Marinus Pharmaceuticals (NASDAQ:MRNS) Earns "Overweight" Rating from Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report)'s stock had its "overweight" rating reiterated by equities research analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They presently have a $13.00 target price on the biopharmaceutical company's stock.

A number of other brokerages also recently issued reports on MRNS. StockNews.com downgraded shares of Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, August 22nd. Truist Financial reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $10.25.

Marinus Pharmaceuticals Trading Down 0.7 %

MRNS stock traded down $0.01 during trading on Monday, hitting $1.39. The company had a trading volume of 266,751 shares, compared to its average volume of 1,151,918. The firm has a market capitalization of $76.56 million, a P/E ratio of -0.54 and a beta of 1.13. Marinus Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $11.26. The company has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $3.35. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period last year, the business posted ($0.61) EPS. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. increased its holdings in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 10,500 shares in the last quarter. AQR Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth $28,000. SG Americas Securities LLC purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth $34,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Marinus Pharmaceuticals in the 1st quarter worth $384,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.